Given that CPDI-02 is expected to be cleared more quickly after SQ administration than IM administration, it is possible that curative treatment requires a more sustained localization of CPDI-02 at the site of infection than prophylactic treatment to sufficiently activate C5aR1-bearing cells. The gene discussed is C5AR1; the disease is infection.